292 related articles for article (PubMed ID: 37790935)
1. Deciphering the immunological and prognostic features of bladder cancer through platinum-resistance-related genes analysis and identifying potential therapeutic target P4HB.
Xiong S; Li S; Zeng J; Nie J; Liu T; Liu X; Chen L; Fu B; Deng J; Xu S
Front Immunol; 2023; 14():1253586. PubMed ID: 37790935
[TBL] [Abstract][Full Text] [Related]
2. Establishment of prognostic model of bladder cancer based on apoptosis-related genes, in which P4HB promotes BLCA progression.
Zou Z; Li Z; Sun W; Gao W; Liu B; Liu J; Guo Y
BMC Urol; 2023 Oct; 23(1):167. PubMed ID: 37845668
[TBL] [Abstract][Full Text] [Related]
3. P4HB: A novel diagnostic and prognostic biomarker for bladder carcinoma.
Wu Y; Peng Y; Guan B; He A; Yang K; He S; Gong Y; Li X; Zhou L
Oncol Lett; 2021 Feb; 21(2):95. PubMed ID: 33376528
[TBL] [Abstract][Full Text] [Related]
4. TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer.
Tang R; Wang H; Liu J; Song L; Hou H; Liu M; Wang J; Wang J
Eur J Med Res; 2024 Feb; 29(1):112. PubMed ID: 38336764
[TBL] [Abstract][Full Text] [Related]
5. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer.
Chi M; Liu J; Mei C; Shi Y; Liu N; Jiang X; Liu C; Xue N; Hong H; Xie J; Sun X; Yin B; Meng X; Wang B
J Exp Clin Cancer Res; 2022 May; 41(1):175. PubMed ID: 35581606
[TBL] [Abstract][Full Text] [Related]
6. Crosstalk of disulfidptosis-related subtypes, establishment of a prognostic signature and immune infiltration characteristics in bladder cancer based on a machine learning survival framework.
Zhao S; Wang L; Ding W; Ye B; Cheng C; Shao J; Liu J; Zhou H
Front Endocrinol (Lausanne); 2023; 14():1180404. PubMed ID: 37152941
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals dynamic changes in the tumor immune microenvironment of bladder cancer and establishes a prognostic model.
Tan Z; Chen X; Zuo J; Fu S; Wang H; Wang J
J Transl Med; 2023 Mar; 21(1):223. PubMed ID: 36973787
[TBL] [Abstract][Full Text] [Related]
8. Identification of a novel signature based on unfolded protein response-related gene for predicting prognosis in bladder cancer.
Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
Hum Genomics; 2021 Dec; 15(1):73. PubMed ID: 34930465
[TBL] [Abstract][Full Text] [Related]
9. A novel metabolic subtype with S100A7 high expression represents poor prognosis and immuno-suppressive tumor microenvironment in bladder cancer.
Cai Y; Cheng Y; Wang Z; Li L; Qian Z; Xia W; Yu W
BMC Cancer; 2023 Aug; 23(1):725. PubMed ID: 37543645
[TBL] [Abstract][Full Text] [Related]
10. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
Wang Z; Tu L; Chen M; Tong S
BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
[TBL] [Abstract][Full Text] [Related]
11. Prognostic model development and molecular subtypes identification in bladder urothelial cancer by oxidative stress signatures.
Dong Y; Wu X; Xu C; Hameed Y; Abdel-Maksoud MA; Almanaa TN; Kotob MH; Al-Qahtani WH; Mahmoud AM; Cho WC; Li C
Aging (Albany NY); 2024 Feb; 16(3):2591-2616. PubMed ID: 38305808
[TBL] [Abstract][Full Text] [Related]
12. Prognosis analysis and validation of lipid metabolism-associated lncRNAs and tumor immune microenvironment in bladder cancer.
Tan Z; Fu S; Zuo J; Wang J; Wang H
Aging (Albany NY); 2023 Aug; 15(16):8384-8407. PubMed ID: 37632832
[TBL] [Abstract][Full Text] [Related]
13. Prolyl 4-hydroxylase subunit beta (P4HB) could serve as a prognostic and radiosensitivity biomarker for prostate cancer patients.
Feng D; Li L; Li D; Wu R; Zhu W; Wang J; Ye L; Han P
Eur J Med Res; 2023 Jul; 28(1):245. PubMed ID: 37480146
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive characterization of endoplasmic reticulum stress in bladder cancer revealing the association with tumor immune microenvironment and prognosis.
Lin Y; Li T; Li Z; Shen C; Wu Z; Zhang Z; Li Z; Yang S; Wang Z; Li P; Fu C; Guo J; Hu H
Front Genet; 2023; 14():1097179. PubMed ID: 37091788
[No Abstract] [Full Text] [Related]
15. Uncovering the potential functions of lymph node metastasis-associated aberrant methylation differentially expressed genes and their association with the immune infiltration and prognosis in bladder urothelial carcinoma.
Gao W; Zhang J; Tian T; Fu Z; Bai L; Yang Y; Wu Q; Wang W; Guo Y
PeerJ; 2023; 11():e15284. PubMed ID: 37123010
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of a model based on immunogenic cell death related genes to predict the prognosis and immune response to bladder urothelial carcinoma.
Chen L; Lin J; Wen Y; Chen Y; Chen CB
Front Oncol; 2023; 13():1291720. PubMed ID: 38023241
[TBL] [Abstract][Full Text] [Related]
17. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
18. Tumor stemness score to estimate epithelial-to-mesenchymal transition (EMT) and cancer stem cells (CSCs) characterization and to predict the prognosis and immunotherapy response in bladder urothelial carcinoma.
Zhang Y; Zhang X; Huang X; Tang X; Zhang M; Li Z; Hu X; Zhang M; Wang X; Yan Y
Stem Cell Res Ther; 2023 Feb; 14(1):15. PubMed ID: 36721217
[TBL] [Abstract][Full Text] [Related]
19. Identification of clinical prognostic factors and analysis of ferroptosis-related gene signatures in the bladder cancer immune microenvironment.
Ma J; Hu J; Zhao L; Wu Z; Li R; Deng W
BMC Urol; 2024 Jan; 24(1):6. PubMed ID: 38172792
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer.
Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
Lipids Health Dis; 2021 Oct; 20(1):146. PubMed ID: 34706720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]